GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence ...

This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.

Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type ...

Recent studies show that GLP-1 receptor agonists are associated with a significantly reduced risk of age-related cataracts ...

Treatment with glucagon-like peptide-1 receptor agonists was associated with lower probabilities of heart, kidney, and lung complications after partial nephrectomy for RCC.

Lilly is investigating retatrutide in seven other Phase III trials, which are due to read out in 2026.

A new review of nearly 100,000 participants suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), popular ...

The Alabama facility is part of the $27bn investment Eli Lilly has pledged to expand its US footprint.

Leerink analyst David Risinger notes that Pfizer (PFE) disclosed on December 9, 2025, that it entered into an exclusive global collaboration and ...

Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...

A major moment in India’s fight against type-2 diabetes arrived this week with the launch of Ozempic, the globally popular semaglutide drug known for its strong effects on blood sugar control and ...

In a retrospective analysis, patients with colon cancer taking GLP-1 agonists had a 62% lower risk of 5-year mortality compared with those not taking the drugs. The mortality benefit was statistically ...